Illumina (California-based biotechnology company) and the Center for Data-Driven Discovery in Biomedicine – D3b (a translational research center focused on accelerating cures for pediatric cancer and rare diseases, based at the Children’s Hospital of Philadelphia) have announced a data partnership aimed at accelerating research into pediatric cancer and rare diseases. Through this initiative, D3b is utilizing Illumina’s cloud-based software and DRAGEN v4.4 algorithms to analyze 100,000 whole genomes from pediatric patients. This effort creates one of the largest unified genomic datasets ever assembled, designed to break down data silos and enable real-time, cross-cohort analysis for the global research community.
The resulting insights will be made available through the Gabriella Miller Kids First Data Resource Center to empower clinicians in uncovering the biological origins of congenital conditions. By identifying structural variants and correcting previous bioinformatic errors, the collaboration seeks to transition genomic discovery into routine clinical decision-making. Furthermore, Illumina is joining D3b in supporting the ARPA-H Pediatric Care eXpansion program, which aims to shorten the patient care journey from months to weeks by connecting over 200 pediatric institutions across the United States. This national data exchange will provide healthcare providers with seamless access to real-world patient trajectories, ultimately establishing a new standard for personalized pediatric precision medicine.
